186 related articles for article (PubMed ID: 15382065)
1. PTEN promoter is methylated in a proportion of invasive breast cancers.
Khan S; Kumagai T; Vora J; Bose N; Sehgal I; Koeffler PH; Bose S
Int J Cancer; 2004 Nov; 112(3):407-10. PubMed ID: 15382065
[TBL] [Abstract][Full Text] [Related]
2. Promoter methylation of the PTEN gene is a common molecular change in breast cancer.
García JM; Silva J; Peña C; Garcia V; Rodríguez R; Cruz MA; Cantos B; Provencio M; España P; Bonilla F
Genes Chromosomes Cancer; 2004 Oct; 41(2):117-24. PubMed ID: 15287024
[TBL] [Abstract][Full Text] [Related]
3. Considerations when analyzing the methylation status of PTEN tumor suppressor gene.
Zysman MA; Chapman WB; Bapat B
Am J Pathol; 2002 Mar; 160(3):795-800. PubMed ID: 11891178
[TBL] [Abstract][Full Text] [Related]
4. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.
Soria JC; Lee HY; Lee JI; Wang L; Issa JP; Kemp BL; Liu DD; Kurie JM; Mao L; Khuri FR
Clin Cancer Res; 2002 May; 8(5):1178-84. PubMed ID: 12006535
[TBL] [Abstract][Full Text] [Related]
5. Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer.
Frisk T; Foukakis T; Dwight T; Lundberg J; Höög A; Wallin G; Eng C; Zedenius J; Larsson C
Genes Chromosomes Cancer; 2002 Sep; 35(1):74-80. PubMed ID: 12203792
[TBL] [Abstract][Full Text] [Related]
6. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas.
Virmani AK; Rathi A; Sathyanarayana UG; Padar A; Huang CX; Cunnigham HT; Farinas AJ; Milchgrub S; Euhus DM; Gilcrease M; Herman J; Minna JD; Gazdar AF
Clin Cancer Res; 2001 Jul; 7(7):1998-2004. PubMed ID: 11448917
[TBL] [Abstract][Full Text] [Related]
7. Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression.
Salvesen HB; Stefansson I; Kretzschmar EI; Gruber P; MacDonald ND; Ryan A; Jacobs IJ; Akslen LA; Das S
Int J Oncol; 2004 Dec; 25(6):1615-23. PubMed ID: 15547698
[TBL] [Abstract][Full Text] [Related]
8. CCND1- and ERBB2-gene deregulation and PTEN mutation analyses in invasive lobular carcinoma of the breast.
Mercapide J; Zhang SY; Fan X; Furió-Bacete V; Schneider J; López de la Osa I; Patchefsky AS; Klein-Szanto AJ; Castresana JS
Mol Carcinog; 2002 Sep; 35(1):6-12. PubMed ID: 12203362
[TBL] [Abstract][Full Text] [Related]
9. Association of the hypermethylation status of PTEN tumor suppressor gene with the risk of breast cancer among Kurdish population from Western Iran.
Yari K; Payandeh M; Rahimi Z
Tumour Biol; 2016 Jun; 37(6):8145-52. PubMed ID: 26715274
[TBL] [Abstract][Full Text] [Related]
10. Association of sporadic breast cancer with PTEN/MMAC1/TEP1 promoter hypermethylation.
Sadeq V; Isar N; Manoochehr T
Med Oncol; 2011 Jun; 28(2):420-3. PubMed ID: 20237868
[TBL] [Abstract][Full Text] [Related]
11. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
12. Altered transcription and expression of PTEN in breast tumors: is it regulated by hypermethylation?
Shetty PJ; Pasupuleti N; Chava S; Nasaruddin K; Hasan Q
Breast Dis; 2011; 33(1):27-33. PubMed ID: 21846942
[TBL] [Abstract][Full Text] [Related]
13. A study on promoter methylation of PTEN in sporadic breast cancer patients from North India.
Siddiqui S; Akhter N; Deo SV; Shukla NK; Husain SA
Breast Cancer; 2016 Nov; 23(6):922-931. PubMed ID: 26754093
[TBL] [Abstract][Full Text] [Related]
14. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas.
Freihoff D; Kempe A; Beste B; Wappenschmidt B; Kreyer E; Hayashi Y; Meindl A; Krebs D; Wiestler OD; von Deimling A; Schmutzler RK
Br J Cancer; 1999 Feb; 79(5-6):754-8. PubMed ID: 10070865
[TBL] [Abstract][Full Text] [Related]
15. PTEN promoter methylation and protein expression in normal early placentas and hydatidiform moles.
Chen H; Ye D; Xie X; Lu W; Zhu C; Chen X
J Soc Gynecol Investig; 2005 Apr; 12(3):214-7. PubMed ID: 15784509
[TBL] [Abstract][Full Text] [Related]
16. PTEN methylation and expression in glioblastomas.
Baeza N; Weller M; Yonekawa Y; Kleihues P; Ohgaki H
Acta Neuropathol; 2003 Nov; 106(5):479-85. PubMed ID: 12904991
[TBL] [Abstract][Full Text] [Related]
17. Genetic and epigenetic alterations of the PTEN gene in soft tissue sarcomas.
Kawaguchi K; Oda Y; Saito T; Takahira T; Yamamoto H; Tamiya S; Iwamoto Y; Tsuneyoshi M
Hum Pathol; 2005 Apr; 36(4):357-63. PubMed ID: 15891996
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.
Takahashi Y; Miyoshi Y; Takahata C; Irahara N; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2005 Feb; 11(4):1380-5. PubMed ID: 15746036
[TBL] [Abstract][Full Text] [Related]
20. Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations.
Barekati Z; Radpour R; Kohler C; Zhang B; Toniolo P; Lenner P; Lv Q; Zheng H; Zhong XY
Hum Mol Genet; 2010 Aug; 19(15):2936-46. PubMed ID: 20466735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
